Entera Bio (NASDAQ:ENTX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 470.71% from the stock's current price.
Entera Bio Stock Performance
Shares of Entera Bio stock traded down $0.12 on Monday, reaching $1.75. 18,328 shares of the stock were exchanged, compared to its average volume of 129,086. Entera Bio has a one year low of $0.52 and a one year high of $3.35. The firm has a market cap of $62.70 million, a PE ratio of -6.68 and a beta of 1.57. The firm's 50 day moving average is $1.77 and its 200-day moving average is $1.96.
Entera Bio (NASDAQ:ENTX - Get Free Report) last issued its earnings results on Friday, August 9th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $0.06 million for the quarter. On average, equities research analysts expect that Entera Bio will post -0.23 EPS for the current fiscal year.
Institutional Trading of Entera Bio
An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC acquired a new stake in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 22,040 shares of the company's stock, valued at approximately $37,000. Hedge funds and other institutional investors own 14.11% of the company's stock.
About Entera Bio
(
Get Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Featured Stories
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
